Last updated on March 2018

The Use of Oracea and Epiduo Forte in Severe Acne Patients


Brief description of study

This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4, 8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. We will evaluate Investigator Global Assessment (IGA), total lesion count, inflammatory lesion count, non-inflammatory lesion count, adverse events and concomitant medications.

Detailed Study Description

This is a single-center, open label pilot study. The study is comprised of 5 study visits; Screening, Baseline, and weeks 4,8, and 12. All subjects will receive Oracea once daily (QD) and Epiduo Forte at Baseline. WE will evaluate Investigator Global Assessment (IGA), total lesion count, adverse events and concomitant medications.

Clinical Study Identifier: NCT03457636

Contact Investigators or Research Sites near you

Start Over

Leon H. Kircik, M.D.

Skin Sciences, PLLC
Louisville, KY United States
  Connect »